DAWN insider trading
HealthcareDay One Biopharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Company website: dayonebio.com
DAWN insider activity at a glance
FilingIQ has scored 629 insider transactions for DAWN since Jun 1, 2021. The most recent filing in our index is dated Apr 23, 2026.
Across the full history, 17 open-market purchases
and 181 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DAWN insider trades is 56.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DAWN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding DAWN
Frequently asked
- How many insider trades does FilingIQ track for DAWN?
- FilingIQ tracks 629 Form 4 insider transactions for DAWN (Day One Biopharmaceuticals, Inc.), covering filings from Jun 1, 2021 onwards. 139 of those were filed in the last 90 days.
- Are DAWN insiders net buyers or net sellers?
- Across the full Form 4 history for DAWN, 17 transactions (3%) were open-market purchases and 181 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DAWN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is DAWN in?
- Day One Biopharmaceuticals, Inc. (DAWN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.19B.
Methodology & sources
Every DAWN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.